Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTPRB | P23467 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416512 | 1.00 | LDHA (0.49) | LDHAHCAR2ALOX15PKMPTPN7 | |
| SCHEMBL15545501 | 0.84 | PDK2 (0.42) | HCAR2 | |
| SCHEMBL4739457 | 0.79 | LDHA (0.55) | LDHAALOX15PKMPTPN7LMNA | |
| SCHEMBL14599861 | 0.79 | HCAR2 (0.47) | HCAR2ALOX15PTPN7LMNAHSD17B10 | |
| SCHEMBL2841832 | 0.79 | CHRNB2 (0.50) | HCAR2ALOX15MCL1 | |
| SCHEMBL20974260 | 0.78 | PPARD (0.47) | ALOX15PKMAGBL2SMN1; SMN2 | |
| SCHEMBL22588114 | 0.76 | LDHA (0.47) | LDHAALOX15PTPN7LMNAALDH1A1 | |
| SCHEMBL29689706 | 0.76 | LDHA (0.47) | LDHAALOX15PTPN7LMNAALDH1A1 | |
| Bicarbonate SCHEMBL29632703 | 0.76 | HCAR2 (0.41) | HCAR2 | |
| SCHEMBL9649335 | 0.76 | HCAR2 (0.52) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230117605-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3952902-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021225912-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210017171-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| EP-3761980-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-112135612-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2020210404-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10793564-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
| WO-2019173653-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | LDHA 4392/4885HCAR2 3094/4885ALOX15 2220/4885 |
| US-20230117605-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | ITGB6, ITGA6, ITGAV | LDHA 4370/4885HCAR2 3688/4885ALOX15 2582/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | LDHA 4370/4885HCAR2 3688/4885ALOX15 2582/4885 |
| US-10793564-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | LDHA 4392/4885HCAR2 3094/4885ALOX15 2220/4885 |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | LDHA 4392/4885HCAR2 3094/4885ALOX15 2220/4885 |
| US-20210017171-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | LDHA 4392/4885HCAR2 3094/4885ALOX15 2220/4885 |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | ITGB6, ITGA6, ITGAV | LDHA 4370/4885HCAR2 3688/4885ALOX15 2582/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | LDHA 4209/4885HCAR2 984/4885ALOX15 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.